Grants Search Results

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners. Pediatric brain tumors are the leading cause of cancer-related deaths in children, and atypical teratoid/rhabdoid tumors (ATRT) are among the most aggressive, with a dismal prognosis. Moreover, treatment related toxicities of current standard therapies cause long term health issues. Researchers at Stanford University, as part of the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team, recently discovered that 100% of ATRT tumors express a protein called B7-H3 and demonstrated that this can be a novel target for cancer immunotherapy. Chimeric Antigen Receptor (CAR) T cells targeting B7-H3 demonstrated dramatic responses against preclinical models of ATRT. They further demonstrated that CAR T cells administered into the central nervous system were more potent and less toxic than systemically administered CAR T cells. This therapy has the potential to dramatically alter outcome for children with these aggressive cancers, and researchers are working towards translating the recent findings into the clinic. A portion of this project is generously supported by Hope4ATRT, a St. Baldrick's charity partner. Zion Yamoah was diagnosed with an aggressive brain tumor called AT/RT just before his third birthday and passed away 15 months later. His love of music and his bright spirit inspired his parents to establish Hope4ATRT. Its mission is to raise funds for innovative research specifically targeted for AT/RT while also helping families to navigate available treatment options and current research in the field. A portion of this project is generously supported by Bianka's Butterfly Fund for PNET Brain Tumor Research, a St. Baldrick's Hero Fund. Four-year old Bianka Kucelin was diagnosed with a malignant brain cancer known as PNET. Despite extensive treatment, the little girl who loved butterflies passed away in May 2015. Bianka will be remembered for her joyful spirit and courageous grace. This Hero Fund honors her life and aspires to fund PNET research grants.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

Immunotherapy is an exceedingly promising approach to transform the way we treat childhood cancers, increasing cures while decreasing toxicity. The St. Baldrick's Foundation EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer) brings together experts from the fields of genomics and immunotherapy from across North America. This team is developing new, targeted immunotherapies for the most difficult to cure childhood cancers. Discoveries are made through basic, translational, and clinical studies conducted in parallel, catalyzing progress in each sphere. The goals are to discover molecules on pediatric cancers that are targetable using immunotherapies, and to develop new therapeutics to target children's cancers. This focus is complementary with other genomic and immunotherapy consortia. The SBF-EPICC team conducts early phase clinical trials of promising immunotherapies throughout North America with a focus on understanding mechanisms of resistance to current approaches as a first step toward developing next generation therapeutics. The team is made up of researchers at ten institutions: Baylor College of Medicine, British Columbia Cancer Agency, Children's Hospital of Philadelphia, Hospital for Sick Children, National Cancer Institute, Seattle Children's Hospital, Stanford University, University of Colorado Denver, University of Pittsburgh, and University of Wisconsin. Funds administered by The Children's Hospital of Philadelphia. This team began in 2013 as the Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team. In 2022, the work continues as the St. Baldrick's EPICC Team (Empowering Pediatric Immunotherapies for Childhood Cancer Team), with continued funding from St. Baldrick's and funding partners.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

Children with cancer can often be successfully treated with chemotherapy drugs that can unfortunately damage the heart in the process. Development of an effective method to prevent this type of injury while curing the cancer is very important. This consortium's goal is to give children successfully cured of cancer the greatest chance of having a completely healthy life afterwards, free of treatment-related side effects. The study is to determine whether a drug called dexrazoxane, which appears to be safe and effective in adults in preventing chemotherapy-related heart injury, can be similarly safe and effective when used in children. Funds administered by Fred Hutchinson Cancer Research Center.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Comprehensive Approach to Improve Medication Adherence in Pediatric ALL. For a description of this project, see the consortium grant made to the lead institution: the University of Alabama at Birmingham, Birmingham, AL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Comprehensive Approach to Improve Medication Adherence in Pediatric ALL. For a description of this project, see the consortium grant made to the lead institution: the University of Alabama at Birmingham, Birmingham, AL.

Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma. The two main subtypes, embryonal and alveolar, are defined by their appearance under the microscope. However, identification of a unique gene mutation in alveolar rhabdomyosarcoma identifies a subgroup with worse prognosis. Future studies may use this gene mutation rather than microscopic appearance to determine risk stratification and treatment, but before instituting this strategy researchers must confirm the role of fusion status in low-risk and metastatic rhabdomyosarcoma. This consortium is examining low-risk and high-risk clinical trials of the COG (Children's Oncology Group) to confirm the importance of fusion status in determining treatment for patients with rhabdomyosarcoma. Awarded at Oregon Health & Science University and transferred to Seattle Children's Hospital.

One of 5 children with acute lymphoblastic leukemia suffers a relapse within 5 years of diagnosis. Also, Hispanic and African American children are more likely to relapse. Research has shown that 44% of the children are non-adherent to oral chemotherapy and that non-adherence is associated with an increased risk of relapse. This consortium has created a comprehensive package of interventions to improve adherence to oral chemotherapy. It is believed that this improvement in adherence will directly translate into an improvement in survival and a higher number of children cured of their cancer. Awarded at the Beckman Research Institute of the City of Hope and transferred to the University of Alabama at Birmingham. Funds administered by the University of Alabama at Birmingham.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Prognostic significance of gene fusion in low or high risk rhabdomyosarcoma. For a description of this project, see the consortium grant made to the lead institution: Seattle Children's Hospital, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Comprehensive Approach to Improve Medication Adherence in Pediatric ALL. For a description of this project, see the consortium grant made to the lead institution: the University of Alabama at Birmingham, Birmingham, AL.